NEWS

Israel’s Zebra Medical gets FDA ok for AI chest X-ray product

May 13, 2019

Zebra Medical Vision said on Monday it received approval from the U.S. Food and Drug Administration for its artificial intelligence-based chest X-ray triage product.

Read More

Computational Pathology Pioneer Ibex Raises $11M

March 26, 2019

aMoon Fund leads round into developer of first ever clinically deployed AI Based Cancer Diagnosis system

Read More

Israeli migraine device co Theranica raises $35m

March 18, 2019

Nerivio Migra, the Netanya-based company’s novel remote neuromodulation device for acute treatment of migraine, is under review by the FDA.

Read More

Israeli health fund aMoon II raises $660 million

March 6, 2019

Israel-based healthcare fund aMoon II said on Wednesday it has received commitments of $660 million from investors. This is up from $600 million reported in January in an investor document obtained by Reuters.

Read More

A healthcare investment fund has become one of Israel’s largest with a $660 million close

March 6, 2019

One of Israel’s single largest venture capital funds is a new later stage vehicle focused on healthcare.

Read More

Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma

March 4, 2019

Results support the clinical development of AL101 as a targeted monotherapy for people with tumors bearing Notch activated mutations

Read More

Regenera Pharma Enrolls First Patient in US Phase 3 Study of RPh201 in NAION

August 2, 2018

Advances Phase 2 Study in Alzheimer’s Disease in Canada, RPh201 development in US supported by Fast Track Designation by US Food and Drug Administration

Read More

Israeli firm creates particles to kill germs on contact, fight bacterial disease

August 2, 2018

With product initially aimed for dental industry, Petah-Tikva based Nobio raises $3.6 million from aMoon Fund and Dr. Ole Jensen, a US surgeon and dentist

Read More

Zebra Medical Vision gets $30M Series C to create AI-based tools for radiologists

June 7, 2018

Zebra Medical Vision, an Israeli medical imaging startup that uses machine and deep learning to build tools for radiologists, has raised a $30 million Series C led by health technology fund aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation—JJDC Inc.

Read More

Medial EarlySign’s clinical validation trial shows promise for detecting colorectal cancer

April 17, 2018

A new clinical validation study, published in the Journal of Clinical Oncology CCI, found that Medial EarlySign’s artificial intelligence tool flagged about 8 percent of patients in a large trial group that were later diagnosed with cancer or precancerous lesions.

Read More

Gains in tRNAslation: It’s time for investors to realize the potential of European RNA technologies

November 2, 2020

Dr. Gur Roshwalb, aMoon Managing Director, discusses how investing in new innovative RNA technologies can lead to rapid value creation, and why Europe is a fertile ground to hunt for them.

Read More

Remote electric neuromodulation device approval extended to treatment of chronic migraine

October 27, 2020

The Food and Drug Administration (FDA) has expanded the approval of Nerivio® (Theranica) to include acute treatment of migraine with or without aura in patients aged 18 years and older with chronic migraine. Previously, the device had only been approved in those with episodic migraine.

Read More

Combining machine learning tools for medical imaging with genetic sequencing nets Sophia Genetics $110M

October 1, 2020

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics added another $110 million to its coffers in a series F financing led by aMoon and Hitachi Ventures.

Read More

Venture capitalists find more to Israel than Zionism

September 30, 2020

Not all olim arrive in Israel to serve in the IDF or go to university. In the case of two aMoon executives, coming to Israel was a way to advance their careers in venture capital health investments while also reaching the goal of living in the Jewish state.

Read More

Alexa, do I have COVID-19?

September 30, 2020

In March, as the staggering scope of the pandemic started to become clear, officials around the world began enlisting the public to join in the fight. In Israel, the defense ministry and a start-up company called Vocalis Health asked people to donate their voices.

Read More

Adicet Announces Completion of Merger with resTORbio

September 15, 2020

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc

Read More

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing

September 15, 2020

Seer, Inc., an aMoon2 portfolio company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc.

Read More

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

September 10, 2020

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund.

Read More

MOBILion Closes $35M Series B Financing Round

August 17, 2020

aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery

Read More

Roche invests millions in Israel’s health tech sector

August 11, 2020

has entered into a partnership agreement with aMoon, an Israeli venture capital company focused on health technology and science. The “StarFinder Lab” collaboration is aiming to help young startups develop innovative diagnostic tools to tackle global health care challenges.

Read More